Pluto Bioinformatics

GSE127948: HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma

Bulk RNA sequencing

Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used unbiased multi-omics and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. SOURCE: Chia-Ho Cheng (chia-ho.cheng@moffitt.org) - Cancer Informatics Core Moffitt Cancer Center